CD53

Across TCGA pan-cancer cohorts, CD53 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CD53 data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher CD53 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CD53 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

COAD, PDAC, and LUAD are the cancer types where CD53 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	All	0.920	1.000	.015	78	view →
PDAC	OS	Median	III,IV	0.306	0.579	.006	35	view →
LUAD	DFS	Median	All	0.798	0.454	.005	14	view →
LSCC	DFS	Tertile	III,IV	0.979	0.593	.043	6	view →
CCRCC	DFS	Quartile	III,IV	0.259	0.749	.022	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CD53–COAD (DFS)

Open the COAD breakdown →